SAN FRANCISCO, May 7 - Myriad Genetics today reported increased revenue and widened losses for the third quarter of fiscal 2002.
Total revenue for the third quarter ended March 31 was $13.1 million compared with $11.6 million in the year-ago period.
The net loss for the quarter was $3.5 million, or $.15 per share, compared to $1.7 million, or $.07 a share, for the same period a year ago.
R&D spending for the quarter rose to approximately $8.7 million from $8.4 million for the year-ago period.
The company said it had $125.7 million in cash and investments as of March 31.
Click here for more information.